| 纯度 | >98%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL13RA1 |
| Uniprot No | P78552 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-343aa |
| 氨基酸序列 | GGGGAAPTETQPPVTNLSVSVENLCTVIWTWNPPEGASSNCSLWYFSHFG DKQDKKIAPETRRSIEVPLNERICLQVGSQCSTNESEKPSILVEKCISPP EGDPESAVTELQCIWHNLSYMKCSWLPGRNTSPDTNYTLYYWHRSLEKIH QCENIFREGQYFGCSFDLTKVKDSSFEQHSVQIMVKDNAGKIKPSFNIVP LTSRVKPDPPHIKNLSFHNDDLYVQWENPQNFISRCLFYEVEVNNSQTET HNVFYVQEAKCENPEFERNVENTSCFMVPGVLPDTLNTVRIRVKTNKLCY EDDKLWSNWSQEMSIGKKRNST |
| 预测分子量 | 38 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL13RA1重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：*"Structural and functional characterization of recombinant human IL-13 receptor α1 protein"*
**作者**：Smith, A.B., et al.
**摘要**：研究通过大肠杆菌表达系统制备重组人IL13RA1胞外域蛋白，并利用X射线晶体学解析其三维结构，揭示了其与IL-13结合的分子机制，为靶向药物设计提供依据。
2. **文献名称**：*"Targeted therapy of glioblastoma using engineered extracellular vesicles displaying interleukin-13 receptor α1-specific ligands"*
**作者**：Wang, Y., et al.
**摘要**：开发了一种基于重组IL13RA1蛋白配体的细胞外囊泡递送系统，实验显示其在胶质母细胞瘤模型中能特异性靶向肿瘤细胞并增强化疗药物递送效率。
3. **文献名称**：*"IL-13 receptor α1 signaling requires a scaffold protein, FAM120A, for activation of the JAK/STAT pathway in allergic asthma"*
**作者**：Lee, J.K., et al.
**摘要**：通过重组IL13RA1蛋白体外实验，发现FAM120A蛋白是IL-13信号通路中JAK/STAT激活的关键支架分子，阐明了其在过敏性哮喘中的调控机制。
---
注：以上文献为示例，实际引用时建议通过PubMed或Google Scholar以关键词“IL13RA1 recombinant protein”检索最新研究。
**Background of IL13RA1 Recombinant Protein**
Interleukin-13 receptor subunit alpha-1 (IL13RA1) is a transmembrane protein that forms part of the type II interleukin-4 (IL-4) and interleukin-13 (IL-13) receptor complexes. It plays a critical role in mediating immune and inflammatory responses, particularly in allergic reactions, fibrosis, and tumorigenesis. IL13RA1 binds IL-13 with high affinity and partners with IL4RA to initiate downstream signaling via JAK-STAT pathways, influencing Th2 cell differentiation, IgE production, and macrophage activation.
The recombinant IL13RA1 protein is typically produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications and functional integrity. It often includes epitope tags (e.g., Fc or His tags) for purification and detection. Structurally, the recombinant form retains the extracellular domain responsible for ligand binding, enabling studies on receptor-ligand interactions, signaling mechanisms, and inhibitor screening.
IL13RA1 is overexpressed in certain cancers, including glioblastoma and Hodgkin’s lymphoma, where it contributes to tumor survival and immune evasion. This has spurred interest in targeting IL13RA1 for immunotherapy, such as IL13RA1-directed CAR-T cells or antibody-drug conjugates. Notably, IL13RA1-specific therapies have shown promise in early clinical trials for glioblastoma.
In research, recombinant IL13RA1 serves as a tool to investigate IL-13/IL-4 signaling cross-talk, validate therapeutic antibodies, or model pathogenic mechanisms in asthma and fibrosis. Its role in modulating immune responses also makes it relevant for studying autoimmune diseases and tissue remodeling.
Overall, IL13RA1 recombinant protein is a versatile reagent bridging basic research and translational applications, with therapeutic potential in oncology and inflammatory disorders.
×
